Drug Profile
ATI 2307
Alternative Names: ATI 2307; T-2307Latest Information Update: 03 Feb 2023
Price :
$50
*
At a glance
- Originator Toyama Chemical
- Developer FUJIFILM Toyama Chemical
- Class Antifungals; Benzamidines; Piperidines; Small molecules
- Mechanism of Action Mitochondrial protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cryptococcosis
- No development reported Aspergillosis; Candidiasis; Mycoses
Most Recent Events
- 19 Oct 2022 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Cryptococcosis presented at the IDWeek 2022 (IDW-2022)
- 18 Apr 2022 Preclinical development is still ongoing for Cryptococcosis in Japan
- 28 Feb 2022 No recent reports of development identified for phase-I development in Mycoses in USA